USO - Compass Oncology — Tigard, Oregon

USO - Compass Oncology is a clinical research site located in Tigard, Oregon, United States 97223.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

USO - Compass Oncology has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Breast Neoplasms.

Sponsors: Eli Lilly and Company.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Tigard

Browse all research sites in Oregon · View every site in Tigard

• Northwest Cancer Specialists, P.C
• Advanced Research Institute - Tigard
• Northwest Cancer Specialists (Compass Oncology) ( Site 8010)
• GSK Investigational Site
• Northwest Cancer Specialists PC
• Northwest Cancer Specialists
• Research Site
• Compass Oncology - West
• Compass Oncology
• Compass Oncology - Northwest Cancer Specialists
• Advanced Vascular Centers
• Travere Investigational Site

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for USO - Compass Oncology?

USO - Compass Oncology has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has USO - Compass Oncology conducted?

USO - Compass Oncology has 1 clinical trials on record, with 1 currently active. Their work covers Breast Neoplasms.

Is USO - Compass Oncology accredited by Crixeo Clinical Trials?

USO - Compass Oncology has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about USO - Compass Oncology?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.